Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system

Liptrott, Neill J ORCID: 0000-0002-5980-8966, Giardiello, Marco ORCID: 0000-0003-0560-4711, McDonald, Tom O ORCID: 0000-0002-9273-9173, Rannard, Steven P ORCID: 0000-0002-6946-1097 and Owen, Andrew ORCID: 0000-0002-9819-7651
(2017) Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system. NANOMEDICINE, 12 (17). pp. 2043-2054.

[img] Text
2017 LPV SDN v6-NANOMED formatting_revised-2.pdf - Author Accepted Manuscript

Download (1MB)


<h4>Aim</h4>We previously demonstrated that solid drug nanoparticles (SDNs) lopinavir (LPV) dispersed into aqueous media display favorable pharmacokinetics.<h4>Methods</h4>The impact of LPV SDNs on the function and phenotype of primary human T cells and macrophages (primary sites of HIV replication) was investigated.<h4>Results</h4>LPV significantly increased IL-1β (ninefold higher than untreated cells; p = 0.045) and TNF-α (sixfold higher than untreated cells; p = 0.018) secretion from monocyte-derived macrophages, whereas LPV SDNs did not elicit these responses at comparable drug concentrations. LPV SDNs were demonstrated to be immunologically inert to human T cells and monocyte-derived macrophages.<h4>Conclusion</h4>The LPV SDN was demonstrated to exhibit comparable, or favorable behavior compared with an LPV aqueous solution in the employed biocompatibility assessments.

Item Type: Article
Uncontrolled Keywords: antiretroviral nanoformulation, immunotoxicology, macrophages, T cells
Depositing User: Symplectic Admin
Date Deposited: 07 Jul 2017 07:34
Last Modified: 19 Jan 2023 07:00
DOI: 10.2217/nnm-2017-0095
Related URLs: